Apnimed

company

About

Apnimed is a clinical-stage company dedicated to the discovery of novel pharmacologic therapies for sleep apnea and related disorders.

  • 11 - 50

Details

Last Funding Type
Series C
Last Funding Money Raised
$62.50M
Industries
Health Care,Medical,Medical Device
Founded date
Jan 1, 2017
Number Of Employee
11 - 50
Operating Status
Active

Apnimed is a clinical-stage company dedicated to the discovery of novel pharmacologic therapies for sleep apnea and related disorders.

Sleep apnea is a common, serious condition with significant morbidity, increased mortality, and substantial effects on daily functioning. Sleep apnea affects more than 20 million Americans and has serious consequences. OSA is caused by a combination of predisposing anatomical factors and sleep-related decrements of activity in upper airway muscles.

Current treatments primarily rely on positive pressure devices, e.g., CPAP, to maintain airway patency. Less commonly used treatments include mandibular advancement devices, nerve stimulation, and surgical interventions.

Apnimed was founded in 2017 and is located in Cambridge, Massachusetts.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$87.50M
Apnimed has raised a total of $87.50M in funding over 2 rounds. Their latest funding was raised on May 4, 2022 from a Series C round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
May 4, 2022 Series C $62.50M 1 Detail
Mar 25, 2021 Series B $25M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
Apnimed is funded by 1 investors. Columbia Seligman Investments are the most recent investors.
Investor Name Lead Investor Funding Round
Columbia Seligman Investments Series C